Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com
New Developments Warrant Rethinking HCC Transplant Criteria

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock
Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

April 29th 2025

senior scientist | Image credit: Ohio State University
Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
April 28th 2016

Will CMS Accept Offer of a 95% Cheaper Enzalutamide?

Surabhi Dangi-Garimella, PhD
A company in Canada, Biolyse Pharma, has offered to manufacture a generic version of enzalutamide at a significantly lower price than what CMS paid in 2014.
Dr Sophia Smith Highlights the Importance of Patient-Reported Outcomes
April 28th 2016

Dr Sophia Smith Highlights the Importance of Patient-Reported Outcomes

Listening to patient-reported outcomes, especially in clinical trials, is extremely important, especially the array of technology available to collect this information, said Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing.
Site Logo
April 27th 2016

Weight Loss and Cancer Recurrence to Be Evaluated by Dana-Farber

Surabhi Dangi-Garimella, PhD
A collaboration between the Dana-Farber Cancer Institute and the fitness tracking company Fitbit will investigate whether weight loss in women diagnosed with breast cancer can stave off recurrence.
Segment 13: Place for Palliative Care in Clinical Pathways
April 27th 2016

Segment 13: Place for Palliative Care in Clinical Pathways

Panelists explain the need and the challenges with including principles of palliative care in oncology clinical pathways.
Segment 12: Patient Awareness About Clinical Pathways
April 27th 2016

Segment 12: Patient Awareness About Clinical Pathways

Robert Dubois, MD, PhD, shares findings from their recently published study in The American Journal of Managed Care, which showed that patients do not know they are being treated on predetermined pathways.
Segment 11: Can Clinical Pathways Restrict Patient Access?
April 27th 2016

Segment 11: Can Clinical Pathways Restrict Patient Access?

Neither Blase Polite, MD, MPP, not Robert Dubois, MD, PhD, believe that clinical pathways restrict patient access to care.
Segment 10: Can Clinical Pathways Be Personalized?
April 27th 2016

Segment 10: Can Clinical Pathways Be Personalized?

According to Blase Polite, MD, MPP, pathways are well-designed to allow personalized medicine.
Segment 9: Ease of Integrating Pathways Based on Site of Care
April 27th 2016

Segment 9: Ease of Integrating Pathways Based on Site of Care

According to Blase Polite, MD, MPP, it is much harder for a cancer center to adapt care pathways than it is for a smaller clinic.
Segment 8: Pathways as a Means to Deliver High-Value Care
April 27th 2016

Segment 8: Pathways as a Means to Deliver High-Value Care

Expanding the definition of "value" beyond cost, Robert Dubois, MD, PhD, emphasized that clinical pathways need more dynamic quality metrics that provide more than just a snapshot of a patient's performance.
Segment 7: How Flexible Are Oncology Care Pathways?
April 27th 2016

Segment 7: How Flexible Are Oncology Care Pathways?

Panelists discussed whether there is any flexibility woven into the process of developing a clinical pathway, especially if a patient does not respond to a particular therapy or if a clinician wants to include a new therapy that may be better fit.
Segment 6: Standardizing Clinical Pathways Across Health Plans
April 27th 2016

Segment 6: Standardizing Clinical Pathways Across Health Plans

While providers would be relieved of their administrative burden, standardizing care pathways across health plans may not be an easy task, Blase Polite, MD, MPP, explains.
Segment 5: Clinical Pathways - A Shared Decision-Making Tool?
April 27th 2016

Segment 5: Clinical Pathways - A Shared Decision-Making Tool?

Have clinical pathways in oncology developed enough for providers and patients to use them as a shared decision-making tool? Panelists provide insight.
Segment 4: How Rigorous Should Pathway Development Be?
April 27th 2016

Segment 4: How Rigorous Should Pathway Development Be?

Experts discuss the need for guidelines and adequate rigor when developing a care pathway in oncology.
Segment 3: Considerations for Developing a Clinical Pathway
April 27th 2016

Segment 3: Considerations for Developing a Clinical Pathway

What do pathway developers consider as they formulate cancer clinical pathways? Panelists explain.
Segment 2: What Are Oncology Care Pathways?
April 27th 2016

Segment 2: What Are Oncology Care Pathways?

Panel members provide their own perspective on what clinical pathways encompass.
Site Logo
April 27th 2016

Study Disproves Role of Statins in Reducing Risk of CRC, Implicates Cholesterol Instead

Surabhi Dangi-Garimella, PhD
An exhaustive analysis of over a 100,000 individuals has confirmed the absence of unbiased association between statin use and a person’s risk of colorectal cancer; however, an inverse relation of risk and cholesterol levels was identified.
Segment 1: Introduction of Panel Members
April 26th 2016

Segment 1: Introduction of Panel Members

The American Journal of Managed Care convened an expert panel to discuss the development and utility of clinical pathways in oncology care.
Site Logo
April 25th 2016

FDA Approves Cabozantinib for Advanced Renal Cell Carcinoma

Surabhi Dangi-Garimella, PhD
Patients diagnosed with advanced renal cell carcinoma, who have received prior treatment with anti-angiogenic agents, now have the option of being treated with the small molecule inhibitor cabozantinib.
Site Logo
April 25th 2016

Choosing Safe Endocrine Treatment in Breast Cancer Remains Challenging

Surabhi Dangi-Garimella, PhD
This Week in Managed Care: April 23, 2016
April 23rd 2016

This Week in Managed Care: April 23, 2016

This week, the top stories in managed care included the news that UnitedHealth will be exiting most Obamacare exchanges in 2017, and coverage from both the annual meeting of the Academy of Managed Care Pharmacy and the Community Oncology Conference.
Site Logo
April 22nd 2016

5 Takeaways From AMCP's Annual Meeting

Laura Joszt, MA
Cost, biosimilars, and technology dominated the conversations when managed care pharmacists, health plan administrators, physicians, and more gathered for the AMCP Managed Care & Specialty Pharmacy Annual Meeting in San Francisco, April 19-22, 2016.
Site Logo
April 21st 2016

Questions With OCM Participation? Flatiron Health Could Provide Answers

Surabhi Dangi-Garimella, PhD
Flatiron Health has announced the development of a cloud-based electronic health record and an analytics tool to support reporting requirements for those clinics that will be selected to participate in the Oncology Care Model.
Site Logo
April 21st 2016

Medicare Part B Demo Would Increase Reimbursement for Lower-Cost Drugs

Surabhi Dangi-Garimella, PhD
According to Avalere Health, physicians who prescribe lower cost drugs would be reimbursed at a higher rate than those who use more expensive drugs, under the proposed Medicare Part B demo model.
Site Logo
April 21st 2016

What We're Reading: ACA Is Having a Positive Impact on Personal Finances

AJMC Staff
What we're reading, April 21, 2016: Congress keeps things moving on the fight against the opioid epidemic; new paper from the National Bureau of Economic Research finds Medicaid expansion has a broader societal impact; and Novartis faces stiff competition from generic version of Gleevec.
Site Logo
April 20th 2016

What Is Coming in Specialty Pharmacy? A Look at the Near-Term Drug Pipeline

Laura Joszt, MA
AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016 kicked off by delving into the near-term specialty pharmaceutical pipeline with Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts.
Site Logo
April 20th 2016

Clinical Pathways Get an In-Depth Look in Evidence-Based Oncology

The growth of clinical pathways in cancer care brings opportunities to improve quality and control cost, but there are frustrations, too. Physicians want to retain some freedom and are pushing back against the administrative jungle from multiple payers, according to a special issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.
Site Logo
April 20th 2016

Nivolumab OS Data Raise Hopes in Head and Neck Cancer

Surabhi Dangi-Garimella, PhD
An international study evaluating nivolumab in head and neck cancer has found that patients treated with the checkpoint inhibitor were twice as likely to be alive at 1 year after initiating treatment, compared with patients who were given standard chemotherapy.
Dr Steve Miller Highlights the Importance of Working Closely With Oncologists
April 20th 2016

Dr Steve Miller Highlights the Importance of Working Closely With Oncologists

Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
Dr Steven Pearson Outlines Specialty Conditions Impacting Healthcare Spending
April 19th 2016

Dr Steven Pearson Outlines Specialty Conditions Impacting Healthcare Spending

Steven D. Pearson, MD, president of the Institute for Clinical and Economic Review, discussed the specialty conditions that are having the biggest impact on overall healthcare expenditures and pharmaceutical spending.
Site Logo
April 19th 2016

The Future of Specialty Pharmacy: Where Do We Need to Go?

Laura Joszt, MA
The specialty pharmacy industry is unique in many ways, but the price growth for these drugs is no longer sustainable, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
<1
...
102103104105106107108109110
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo